RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Polish Researchers Cite Rutherrin PDT for Brain CancerBenedictus wrote: I revisited that June PR, linked below, to re-read her impressive credentials and was reminded of this comment made by the CoB: "Based on this latest interim clinical data, the Company is commencing to actively explore international partnering, licensing and distribution opportunities for our cancer targeting PDC, Ruvidar™." So, they began this process just 3 months ago. I'd imagine even small regional licensing deals take a while longer than 3 months.
https://www.accesswire.com/759387/TheralaseR-Announces-Appointment-of-New-Independent-Director
Good point Benedictus...The reason Dr Lbiati is already seeking Big Pharma contracts is because the FDA had no major objections to the pre-BTD submission, the FDA is just asking for a minor update and some clarifications on some data of the pre-BTD submission.
(Big Pharma are not dummy, they know that BTD approval is almost a certainty).
Yes! Any deal Dr Lbiati will sign on is conditional to the BTD approval. Unless somebody can find a treatment that has a better CR(36% at 12 months), BTD is in the bag(again big pharma know this).
After the BTD approval, because of Dr Lbiati work we could see 1,2 or 3 contracts(big or small) signed by TLT in a very short time frame.
As usual in between news releases there will be a lot's of talk about management, the SP, Financing...ETC.
But in the end, all the longs on this board know what they have.
" A one in a lifetime opportunity".